Topics

ImmunoCellular Therapeutics, Ltd. and BioWa, Inc. Company Profile

21:08 EST 22nd January 2020 | BioPortfolio

IMUC is a Los Angeles-based clinical-stage company that is developing immune-based therapies for the treatment of brain and other cancers. The Company recently started a Phase II trial of its lead product candidate, ICT-107, a dendritic cell-based vaccine targeting multiple tumor associated antigens for newly diagnosed glioblastoma. To learn more about IMUC, please visit www.imuc.com.


News Articles [772 Associated News Articles listed on BioPortfolio]

Cantargia and BioWa Extend Ongoing Collaboration around the POTELLIGENT Technology

Cantargia AB and BioWa Inc. have signed an extension of the license agreement around the BioWa proprietary POTELLIGENT Technology for production of Cantargia's antibody drug candidate CAN04, which...

ImmunoCellular Therapeutics: Notice of Proposed Settlement of Derivative Action

LOS ANGELES, Aug. 09, 2019 (GLOBE NEWSWIRE) -- ImmunoCellular Therapeutics, Ltd. (“ImmunoCellular”) (OTC: IMUC), today issued the following announcement. The following is being released pursu...

Cantargia, BioWa extend ongoing collaboration around POTELLIGENT technology

Since the original agreement allowing use of POTELLIGENT® Technology was signed in 2015, Cantargia has advanced CAN04 to phase IIa clinical development for potential use in the treatment The post Ca...

Cantargia and BioWa Extend Ongoing Collaboration around the POTELLIGENT® Technology

Cantargia AB and BioWa Inc. have signed an extension of the license agreement around the BioWa proprietary POTELLIGENT® Technology for production of Cantargia’s antibody drug candidate CAN04, whic...

Deals, Deals, Deals: Astellas and Frequency, Orum, ImmunoCellular and Pyxis Oncology http://dlvr.it/R8bJhH pic.twitter.com/KBMEdrmdnf

Deals, Deals, Deals: Astellas and Frequency, Orum, ImmunoCellular and Pyxis Oncology http://dlvr.it/R8bJhH  pic.twitter.com/KBMEdrmdnf

Deals, Deals, Deals: Astellas and Frequency, Orum, ImmunoCellular and Pyxis Oncology

There’s been quite a few small and mid-sized deals announced today. Let’s take a look at four of them.

Global Cancer Targeted Therapy Market Data Survey Report 2025 [Report Updated: 01011970] Prices from USD $1275

SummaryThe global Cancer Targeted Therapy market will reach Volume Million USD in 2018 with CAGR xx% 20182025. The main contents of the report including:Global market size and forecastRegional market ...

Global Cancer Targeted Therapy Market Data Survey Report 2025 [Report Updated: 01011970] Prices from USD $1320

SummaryThe global Cancer Targeted Therapy market will reach Volume Million USD in 2018 with CAGR xx% 20182025. The main contents of the report including:Global market size and forecastRegional market ...

Drugs and Medications [27 Associated Drugs and Medications listed on BioPortfolio]

Kynamro [kastle therapeutics, llc]

NA

Olopatadine hydrochloride [somerset therapeutics, llc]

OLOPATADINE Hydrochloride Ophthalmic Solution USP, 0.1%Somerset Therapeutics, LLC

Oxygen [breathe easy therapeutics, inc]

NA

Diclofenac sodium delayed release [cambridge therapeutics technologies, llc]

Diclofenac Sodium

Olopatadine hydrochloride [a-s medication solutions]

OLOPATADINE Hydrochloride Ophthalmic Solution USP, 0.1%Somerset Therapeutics, LLC

PubMed Articles [416 Associated PubMed Articles listed on BioPortfolio]

Digital Therapeutics: Emerging New Therapy for Neurologic Deficits after Stroke.

Digital therapeutics is an evidence-based intervention using high-quality software, with the sole purpose of treatment. As many healthcare systems are encountering high demands of quality outcomes, th...

Measurement of mRNA therapeutics: method development and validation challenges.

The progression of chemically modified mRNA therapeutics through development pipelines is accelerating for many disease indications and the need to assess these analytes is becoming more routine for t...

Dr E. Keith Borden: Inaugural President of the Canadian Association for Population Therapeutics.

Pharmacovigilance 2030: Invited Commentary for the January 2020 "Futures" Edition of Clinical Pharmacology and Therapeutics.

Metabolism: A Burning Opioid Issue in Obesity Therapeutics.

Food restriction triggers a lowering in body temperature. A new study now provides a mechanism for this process that relies on opioid signaling in the hypothalamus. These observations suggest potentia...

Clinical Trials [205 Associated Clinical Trials listed on BioPortfolio]

Long-term Follow-Up Study Following Treatment With Fate Therapeutics' Engineered Cellular Immunotherapy

The purpose of the study is to assess long-term side effects from subjects who receive a Fate Therapeutics genetically modified NK cell product. Subjects who previously took part in a Fate...

Impact of Ibis on Patients With Advanced COPD

The purpose of this research is to determine if Ibis™, a digital therapeutics solution developed by Senscio Systems, reduces the emergency room visits and hospitalizations of patients wi...

HDL Acute Lipid Optimization in Homozygous Familial Hypercholesterolemia

Assess the effect on coronary atheroma of serial infusions of autologous selectively delipidated HDL/preβ enriched plasma following use of HDL Therapeutics PDS-2™ System

Ontogenesis of the P-Glycoprotein in Human Lymphocytes Influence of HIV and Antiretroviral Therapeutics

The P-glycoprotein (P-gp) is a membranous transporter that modulates the intracellular concentrations of many drugs and plays thus a major role in the efficacy of the therapeutics that act...

A Trial to Find Safe and Active Doses of an Investigational Drug CX-072 for Patients With Solid Tumors or Lymphomas

The purpose of this first-in-human study of CX-072 is to characterize the safety, tolerability, pharmacokinetics (PK), pharmacodynamics (PD) and antitumor activity of CX-072 administered i...

Companies [1419 Associated Companies listed on BioPortfolio]

ImmunoCellular Therapeutics, Ltd. and BioWa, Inc.

IMUC is a Los Angeles-based clinical-stage company that is developing immune-based therapies for the treatment of brain and other cancers. The Company recently started a Phase II ...

BioWa

BioWa’s POTELLIGENT™ service significantly improve the probability of successful mAb development by directly addressing many of the weaknesses that have led to previous failures. More specifically...

BioWa, Inc.

Aeris Therapeutics

Aeris Therapeutics is an emerging medical therapeutics company specializing in the development and commercialization of novel treatments for patients with emphysema and other adva...

Altair Therapeutics, Inc.

Based in San Diego, Altair Therapeutics, Inc. is a privately-held biopharmaceutical company developing novel therapeutics to treat human respiratory diseases. Altair Therap...

More Information about "ImmunoCellular Therapeutics, Ltd. and BioWa, Inc." on BioPortfolio

We have published hundreds of ImmunoCellular Therapeutics, Ltd. and BioWa, Inc. news stories on BioPortfolio along with dozens of ImmunoCellular Therapeutics, Ltd. and BioWa, Inc. Clinical Trials and PubMed Articles about ImmunoCellular Therapeutics, Ltd. and BioWa, Inc. for you to read. In addition to the medical data, news and clinical trials, BioPortfolio also has a large collection of ImmunoCellular Therapeutics, Ltd. and BioWa, Inc. Companies in our database. You can also find out about relevant ImmunoCellular Therapeutics, Ltd. and BioWa, Inc. Drugs and Medications on this site too.

Quick Search

Relevant Topics

Alzheimer's Disease
Of all the types of Dementia, Alzheimer's disease is the most common, affecting around 465,000 people in the UK. Neurons in the brain die, becuase  'plaques' and 'tangles' (mis-folded proteins) form in the brain. People with Al...

Clincial Trials
In a clinical trial or interventional study, participants receive specific interventions according to the research plan or protocol created by the investigators. These interventions may be medical products, such as drugs or devices; procedures; or change...


Corporate Database Quicklinks



Searches Linking to this Company Record